Piha-Paul, S. A., Hierro, C., Matos, I., Boni, V., Hahn, N., Bitting, R., … Tabernero, J. (2020). A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC). In CLINICAL CANCER RESEARCH (Vol. 26, pp. 40–41).

Piha-Paul, Sarina A., Cinta Hierro, Ignacio Matos, Valentina Boni, Noah Hahn, Rhonda Bitting, Todd Bauer, et al. “A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC).” In CLINICAL CANCER RESEARCH, 26:40–41, 2020.

Piha-Paul SA, Hierro C, Matos I, Boni V, Hahn N, Bitting R, et al. A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC). In: CLINICAL CANCER RESEARCH. 2020. p. 40–1.

Piha-Paul, Sarina A., et al. “A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC).” CLINICAL CANCER RESEARCH, vol. 26, no. 15, 2020, pp. 40–41.

Piha-Paul SA, Hierro C, Matos I, Boni V, Hahn N, Bitting R, Bauer T, Rahul A, Meric-Bernstam F, Gourlay S, Owens TD, Brameld K, Neale A, Schwartz R, Murray S, Ucpinar S, Foote P, Venetsanakos E, Tabernero J. A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC). CLINICAL CANCER RESEARCH. 2020. p. 40–41.